(Q44776800)

6 December 2017

Does anthracycline administration by infusion in children affect late cardiotoxicity? (English)

1 reference

6 December 2017

Levitt GA

1

1 reference

6 December 2017

Dorup I

series ordinal

2

1 reference

6 December 2017

Sorensen K

series ordinal

3

1 reference

6 December 2017

Sullivan I

series ordinal

4

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

British Journal of Haematology

6 December 2017

1 reference

6 December 2017

124

1 reference

6 December 2017

463-468

1 reference

6 December 2017

4

1 reference

Statistics notes. Treatment allocation in controlled trials: why randomise?

6 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Randomized versus historical controls for clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04803.X

10.1111/J.1365-2141.2004.04803.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference